JP2015512246A5 - - Google Patents

Download PDF

Info

Publication number
JP2015512246A5
JP2015512246A5 JP2015500675A JP2015500675A JP2015512246A5 JP 2015512246 A5 JP2015512246 A5 JP 2015512246A5 JP 2015500675 A JP2015500675 A JP 2015500675A JP 2015500675 A JP2015500675 A JP 2015500675A JP 2015512246 A5 JP2015512246 A5 JP 2015512246A5
Authority
JP
Japan
Prior art keywords
item
domain
polypeptide
protein
items
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015500675A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015512246A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/032686 external-priority patent/WO2013138795A1/en
Publication of JP2015512246A publication Critical patent/JP2015512246A/ja
Publication of JP2015512246A5 publication Critical patent/JP2015512246A5/ja
Pending legal-status Critical Current

Links

JP2015500675A 2012-03-15 2013-03-15 細胞内抗体および抗体様モイエティの送達のための細胞透過組成物ならびに使用方法 Pending JP2015512246A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261611493P 2012-03-15 2012-03-15
US61/611,493 2012-03-15
PCT/US2013/032686 WO2013138795A1 (en) 2012-03-15 2013-03-15 Cell penetrating compositions for delivery of intracellular antibodies and antibody-like moieties and methods of use

Publications (2)

Publication Number Publication Date
JP2015512246A JP2015512246A (ja) 2015-04-27
JP2015512246A5 true JP2015512246A5 (cg-RX-API-DMAC7.html) 2016-05-12

Family

ID=49161881

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015500675A Pending JP2015512246A (ja) 2012-03-15 2013-03-15 細胞内抗体および抗体様モイエティの送達のための細胞透過組成物ならびに使用方法

Country Status (6)

Country Link
US (1) US20150266939A1 (cg-RX-API-DMAC7.html)
EP (1) EP2825561A4 (cg-RX-API-DMAC7.html)
JP (1) JP2015512246A (cg-RX-API-DMAC7.html)
AU (1) AU2013231851A1 (cg-RX-API-DMAC7.html)
CA (1) CA2867188A1 (cg-RX-API-DMAC7.html)
WO (1) WO2013138795A1 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150307576A1 (en) * 2012-12-07 2015-10-29 Permeon Biologics, Inc. Fgf-10 complexes
US10239957B2 (en) 2013-11-06 2019-03-26 Merck Sharp & Dohme Corp. Peptide containing conjugates for dual molecular delivery of oligonucleotides
SG10201811729PA (en) 2013-12-12 2019-02-27 Life Technologies Corp Membrane-penetrating peptides to enhance transfection and compositions and methods for using same
WO2015109012A1 (en) 2014-01-14 2015-07-23 Integrated Biotherapeutics, Inc. Targeting immunological functions to the site of bacterial infections using cell wall targeting domains of bacteriolysins
US10532083B2 (en) 2014-02-13 2020-01-14 Technische Universität München Methods for inducing differentiation or conversion of white adipocytes and/or preadipocytes to brown adipocites using FGF8
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
CA2967595A1 (en) 2014-11-12 2016-05-19 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2016172187A1 (en) * 2015-04-20 2016-10-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods and compositions related to kras inhibitors
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US9957325B2 (en) * 2015-10-13 2018-05-01 Formurex, Inc. Synthetic antibody mimic peptides
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US10604558B2 (en) * 2016-01-05 2020-03-31 Colorado State University Research Foundation Compositions comprising resurfaced cell-penetrating nanobodies and methods of use thereof
US11318139B2 (en) 2016-01-26 2022-05-03 Dana-Farber Cancer Institute, Inc. Methods for treating brain metastases using combinations of anti-P13K and anti-mTOR agents
CN105837665B (zh) * 2016-05-16 2019-04-30 江苏大学 特异性抑制hb-egf促肿瘤细胞迁移浸润的多肽
US9611297B1 (en) 2016-08-26 2017-04-04 Thrasos Therapeutics Inc. Compositions and methods for the treatment of cast nephropathy and related conditions
WO2018053463A1 (en) 2016-09-19 2018-03-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. Artificial antigen presenting cells for genetic engineering of immune cells
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2018111051A1 (ko) * 2016-12-16 2018-06-21 (주)에빅스젠 세포막 투과 펩티드 및 이를 포함하는 세포내 전달체
CN110139870B (zh) * 2016-12-16 2023-12-01 爱维斯健有限公司 细胞膜穿透肽及包含其的细胞内输送载体
WO2018156735A1 (en) * 2017-02-22 2018-08-30 H. Lee Moffitt Cancer Center And Research Institute, Inc. Bispecific antibody for cancer immunotherapy
JP2020510671A (ja) 2017-03-03 2020-04-09 シアトル ジェネティックス， インコーポレイテッド グリカン相互作用化合物および使用の方法
KR101933217B1 (ko) * 2017-12-28 2018-12-27 (주) 에빅스젠 피부 염증 억제용 펩티드 및 이를 포함하는 피부 염증 예방 또는 치료용 조성물
JP7374502B2 (ja) * 2018-05-03 2023-11-07 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション Ｏｃａ－ｂペプチドコンジュゲート及び処置方法
CN112912103B (zh) * 2018-05-21 2025-08-29 广州邦定生物技术有限公司 多价蛋白质复合物
WO2019240431A1 (ko) * 2018-06-14 2019-12-19 (주) 에빅스젠 세포 투과 펩티드 및 rpe65의 융합 단백질을 포함하는 레버 선천성 흑암시 치료용 약학적 조성물
EP3808762A4 (en) * 2018-06-14 2022-03-30 Avixgen Inc. FUSION PROTEIN BOUND TO CELL PERMEABLE PEPTIDE AND COMPOSITION CONTAINING FUSION PROTEIN OR CELL PERMEABLE PEPTIDE AND EPITHELIAL CELL GROWTH FACTOR AS ACTIVE INGREDIENTS
GB201815045D0 (en) 2018-09-14 2018-10-31 Univ Ulster Bispecific antibody targeting IL-1R1 and NLPR3
US20230076637A1 (en) * 2020-02-06 2023-03-09 Ajou University Industry-Academic Cooperation Foundation Fusion antibody for presenting antigen-derived t cell antigen epitope or peptide containing same on cell surface, and composition comprising same
EP4146801B1 (en) * 2020-05-04 2025-07-02 The Board of Trustees of the Leland Stanford Junior University Compositions, systems, and methods for the generation, identification, and characterization of effector domains for activating and silencing gene expression
JP2023534800A (ja) * 2020-07-13 2023-08-14 ナショナル ユニヴァーシティー オブ シンガポール ウイルスワクチンおよび腫瘍ワクチンの開発、がん免疫療法、ならびに自己免疫疾患の診断および治療における治療用途のためのペプチド性アジュバント
WO2023034993A1 (en) * 2021-09-03 2023-03-09 Gleich Gerald J Compositions and methods for diagnosing, detecting and treating eosinophil-related diseases
CN117736338A (zh) * 2023-12-08 2024-03-22 温州医科大学 一种角质细胞生长因子-透皮肽融合蛋白及其制备与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743422B1 (en) * 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
AU5440800A (en) * 1999-05-21 2000-12-12 Human Genome Sciences, Inc. Fibroblast growth factor 10
EE200200531A (et) * 2002-09-17 2004-04-15 O� InBio Terapeutiliste rakkusisenevate antikehade saamineja kasutamine
WO2010119249A1 (en) * 2009-04-14 2010-10-21 Trojan Technologies Ltd. Therapeutic antennapedia-antibody molecules and methods of use thereof
EP2424877A4 (en) * 2009-04-28 2013-01-02 Harvard College SUPRAGELADENE PROTEINS FOR CELL PENETRATION
US20150307576A1 (en) * 2012-12-07 2015-10-29 Permeon Biologics, Inc. Fgf-10 complexes

Similar Documents

Publication Publication Date Title
JP2015512246A5 (cg-RX-API-DMAC7.html)
MuÈeller-Pillasch et al. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein
EP2040728B1 (en) Fkbp-l and uses thereof as inhibitors of angiogenesis
Kinzler et al. The GLI gene encodes a nuclear protein which binds specific sequences in the human genome
JP2022062012A (ja) 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
JP2022078262A (ja) 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
CN101305020B (zh) 用于诊断和治疗的肿瘤相关抗原的鉴定
JP2003511071A (ja) Ｊｎｋシグナル導入経路の細胞透過性ペプチドインヒビター
TW201406959A (zh) 抗發炎胜肽及包含其之成分（三）
WO2014046481A1 (ko) 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
US20090142350A1 (en) Pancreatic Cancer Genes
KR102060411B1 (ko) 세포 침투성 펩타이드, 이를 포함하는 융합 화합물 및 이 융합 화합물을 포함하는 약학 조성물
JP2008531608A (ja) Ｙｋｌ−４０モノクローナル抗体
KR20190013612A (ko) 인간 항-antxr 키메라 항원 수용체 및 이의 용도
WO1999016790A1 (en) Use of the tumour suppressor gene p33ing1 for modulation of p53 activity and in tumour diagnosis
KR101559974B1 (ko) ｓｉＲＮＡ 전달을 위한 재조합 단백질 및 이를 포함하는 조성물
US20210292390A1 (en) Chimeric antigen receptors
US9683025B2 (en) Methods and compositions for treating cancer and inflammatory diseases
KR102307567B1 (ko) 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
CN108948203A (zh) 抗pd-1单克隆抗体及其制备方法和应用
CN101142233A (zh) 抑制cathelin样蛋白hCAP18/LL-17的试剂
CN107812192B (zh) 抑制znf498蛋白表达量的物质在制备预防和治疗癌症的产品中的应用
CN1948335B (zh) 白念珠菌菌丝调控因子基因及其用途
EP1760087B1 (en) Novel protein complex and use thereof
US20040138161A1 (en) Methods of modulating proliferative conditions